| Literature DB >> 33716201 |
Ana Carolina B da C Rodrigues1, Rafaela G A Costa1, Suellen L R Silva1, Ingrid R S B Dias1, Rosane B Dias1, Daniel P Bezerra2.
Abstract
Acute myeloid leukemia (AML) remains the most lethal of leukemias and a small population of cells called leukemic stem cells (LSCs) has been associated with disease relapses. Some cell signaling pathways play an important role in AML survival, proliferation and self-renewal properties and are abnormally activated or suppressed in LSCs. This includes the NF-κB, Wnt/β-catenin, Hedgehog, Notch, EGFR, JAK/STAT, PI3K/AKT/mTOR, TGF/SMAD and PPAR pathways. This review aimed to discuss these pathways as molecular targets for eliminating AML LSCs. Herein, inhibitors/activators of these pathways were summarized as a potential new anti-AML therapy capable of eliminating LSCs to guide future researches. The clinical use of cell signaling pathways data can be useful to enhance the anti-AML therapy.Entities:
Keywords: Acute myeloid leukemia; Cell signaling; Leukemic stem cells; Target therapy
Mesh:
Substances:
Year: 2021 PMID: 33716201 DOI: 10.1016/j.critrevonc.2021.103277
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN: 1040-8428 Impact factor: 6.312